[1]王文雅 施兰君 胡晶 廖星.适应性卫生技术评估在中医药领域的应用探讨[J].中国卫生质量管理,2025,32(06):006-11.[doi:10.13912/j.cnki.chqm.2025.32.6.02]
　WANG Wenya,SHI Lanjun,HU Jing.Exploration of Adaptive Health Technology Assessment Application in the Field of Traditional Chinese Medicine[J].Chinese Health Quality Management,2025,32(06):006-11.[doi:10.13912/j.cnki.chqm.2025.32.6.02]
点击复制

适应性卫生技术评估在中医药领域的应用探讨()
分享到：

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第32卷
期数:
2025年06期
页码:
006-11
栏目:
特别关注
出版日期:
2025-06-15

文章信息/Info

Title:
Exploration of Adaptive Health Technology Assessment Application in the Field of Traditional Chinese Medicine
作者:
王文雅 施兰君 胡晶 廖星
中国中医科学院中医临床基础医学研究所
Author(s):
WANG Wenya;  SHI Lanjun; HU Jing
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
关键词:
适应性卫生技术评估; 卫生技术评估; 中医药卫生技术
Keywords:
Adaptive Health Technology Assessment;  Health Technology Assessment;  Traditional Chinese Medicine Health Technology
分类号:
R197.32；R2-03
DOI:
10.13912/j.cnki.chqm.2025.32.6.02
文献标志码:
A
摘要:
适应性卫生技术评估（AHTA）通过调整分析时间、数据来源、技术能力和评估实施者，并利用源自其他背景的证据信息生成可靠的HTA结果。开展AHTA通常采用事实HTA、快速综述、快速成本-效益分析、制造商快速提交和迁移五类实施方法。AHTA能够在资源有限的情况下快速提供决策支持，尤其适用于中低收入国家或紧急决策场景等。在中医药领域开展AHTA，可丰富中医药卫生技术评估方法，并满足不同情境下的中医药决策需求，相关机构以及政策制定者、研究人员等应重视AHTA方法在中医药领域的应用，以推动中医药技术纳入医保目录的规范化进程，促进中医药优势特色治疗技术发展。
Abstract:
Adaptive Health Technology Assessment (AHTA) generates reliable Health Technology Assessment (HTA) outcomes by adjusting analysis timelines, data sources, technical capabilities, and assessors, and by leveraging evidence from diverse contexts. Five implementation methods are commonly employed in conducting AHTA,such as factual HTA, rapid review, rapid cost-effectiveness analysis, rapid manufacturer submissions, and transfer. AHTA can swiftly provide decision support under resource constraints, making it particularly suitable for scenarios such as low- and middle-income countries or urgent decision-making contexts. Implementing AHTA in the field of traditional Chinese medicine (TCM) can enrich TCM health technology assessment methodologies and meet the decision-making needs of TCM in various situations. It is recommended that relevant institutions, policymakers, and researchers prioritize the application of AHTA methods in TCM to facilitate the standardized inclusion of TCM technologies in medical insurance catalogs and promote the development of TCM’s advantageous and distinctive therapeutic techniques.

参考文献/References:

［1］O’ROURKE B, OORTWIJN W, SCHULLER T. The new definition of health technology assessment: a milestone in international collaboration［J］. Int J Technol Assess Health Care, 2020,36(3): 187-190.［2］MUNDY L, FORREST B, HUANG LY, et al. Health technology assessment and innovation: here to help or hinder?［J］. Int J Technol Assess Health Care, 2024,40(1): e37.［3］吴雪, 景城阳, 施兰君, 等. 国内外卫生技术评估方法指南的系统评价［J］. 中国循证医学杂志, 2024,24(9): 1021-1029.［4］CHALKIDOU K, LEVINE R, DILLON A. Helping poorer countries make locally informed health decisions［J］. BMJ, 2010,341: c3651.［5］PICHON-RIVIERE A, AUGUSTOVSKI F, GARCA MS, et al. Transferability of health technology assessment reports in Latin America: an exploratory survey of researchers and decision makers［J］. Int J Technol Assess Health Care, 2012,28(2): 180-186.［6］KRIZA C, HANASS-HANCOCK J, ODAME EA, et al. A systematic review of health technology assessment tools in sub-Saharan Africa: methodological issues and implications［J］. Health Res Policy Syst, 2014,12: 66.［7］NEMZOFF C,RUIZ F,CHALKIDOU K, et al. Adaptive health technology assessment to facilitate priority setting in low- and middle-income countries［J］. BMJ Global Health, 2021,6(4): e4549.［8］王海银, 何达, 王贤吉, 等. 国内外卫生技术评估应用进展及建议［J］. 中国卫生政策研究, 2014,7(8): 19-23.［9］DRUMMOND MF, SCHWARTZ JS, JNSSON B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions［J］. Int J Technol Assess Health Care, 2008,24(3): 244-258, 362-368.［10］NEMZOFF C, SHAH HA, HEUPINK LF, et al. Adaptive health technology assessment: a scoping review of methods［J］. Value Health, 2023,26(10): 1549-1557.［11］MERLIN T, TAMBLYN D, ELLERY B. What’s in a name? Developing definitions for common health technology assessment product types of the international network of agencies for health technology assessment (inahta)［J］. Int J Technol Assess Health Care, 2014,30(4): 430-437.［12］MURPHY A, REDMOND S. Rapid reviews with health-technology assessments in reimbursement systems-an examination of ireland as a case study［J］. Global and Regional Health Technology Assessment, 2016,4: e34-e40.［13］LOPERT R, RUIZ F, CHALKIDOU K. Applying rapid ’de-facto’ HTA in resource-limited settings: experience from Romania［J］. Health Policy, 2013,112(3): 202-208.［14］DANK D, MOLNR MP. Balanced assessment systems revisited［J］. J Mark Access Health Policy, 2017,5(1): 1355190.［15］NMETH B, GOETTSCH W, KRISTENSEN FB, et al. The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries［J］. Expert Rev Pharmacoecon Outcomes Res, 2020,20(4): 321-330.［16］李幼平, 喻佳洁, 孙 鑫. 快速评估方法与流程的探索［J］. 中国循证医学杂志, 2014,14(5): 497-500.［17］HAMEL C, MICHAUD A, THUKU M, et al. Defining rapid reviews: a systematic scoping review and thematic analysis of definitions and defining characteristics of rapid reviews［J］. Journal of Clinical Epidemiology, 2021,129: 74-85.［18］FEATHERSTONE RM, DRYDEN DM, FOISY M, et al. Advancing knowledge of rapid reviews: an analysis of results, conclusions and recommendations from published review articles examining rapid reviews［J］. Syst Rev, 2015,4: 50.［19］PANDOR A, KALTENTHALER E, MARTYN-ST JAMES M, et al. Delphi consensus reached to produce a decision tool for SelecTing Approaches for Rapid Reviews (STARR)［J］. Journal of Clinical Epidemiology, 2019,114: 22-29.［20］VARLEY, TILSON L, FOGARTY E, et al. The utility of a rapid review evaluation process to a national HTA Agency［J］. Pharmacoeconomics, 2022,40(2): 203-214.［21］WADMANN S, KJELLBERG J. New model for prioritised adoption and use of hospital medicine in Denmark since 2017: challenges and perspectives［J］. Health Policy, 2019,123(7): 606-610.［22］GOEREE R, HE J, O’REILLY D, et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application［J］. Clinicoecon Outcomes Res, 2011,3: 89-104.［23］BARBIERI M, DRUMMOND M, RUTTEN F, et al. What do international pharmacoeconomic guidelines say about economic data transferability?［J］. Value Health, 2010,13(8): 1028-1037.［24］DRUMMOND M, AUGUSTOVSKI F, KAL Z, et al. Challenges faced in transferring economic evaluations to middle income countries［J］. Int J Technol Assess Health Care, 2015,31(6): 442-448.［25］ALSHREEF A, MACQUILKAN K, DAWKINS B, et al. Cost-effectiveness of docetaxel and paclitaxel for adjuvant treatment of early breast cancer: adaptation of a model-based economic evaluation from the United Kingdom to South Africa［J］. Value Health Reg Issues, 2019,19: 65-74.［26］KAR SS, SIVANANTHAM P, RAVEL V, et al. Cost-effectiveness of emicizumab prophylaxis for haemophilia A with inhibitors: an adaptive health technology assessment for the Indian setting［J］. BMJ Evid Based Med, 2024(5):112492.［27］乔 琛, 张 旭, 杨玉洁, 等. 国际新兴卫生技术水平扫描系统建设经验及启示［J］. 中国循证医学杂志, 2020,20(1): 87-93.［28］廖 星, 郭武栋, 曹 庄, 等. 应用卫生技术评估开展中成药临床综合评价［J］. 中国中药杂志, 2020,45(16): 3749-3758.［29］吴 雪, 王文雅, 廖 星, 等. 中医药卫生技术评估实施规范的构建与内容介绍［J］. 中国中药杂志, 2024,49(20): 5643-5651.［30］王雅星, 谢雁鸣. 国内外卫生技术评估应用现状及对中医药的启示［J］. 天津中医药大学学报, 2024,43(5): 444-449.［31］张碧华,邵 晖,叶爱军,等.血塞通注射液治疗中风的快速卫生技术评估［J］.中国药房,2023,34(1):97-101.［32］陈世祺, 段银银, 王 洁, 等. 尿毒清颗粒治疗慢性肾脏病的快速卫生技术评估［J］. 中国医院用药评价与分析, 2024,24(9): 1123-1126.［33］李苗苗, 赵晖, 戴泽琦, 等. 4种口服中成药治疗便秘的快速卫生技术评估［J］. 中国中药杂志, 2022,47(12): 3144-3154.［34］吕兰婷, 施文凯, 唐佳骥, 等. 中医医院开展医院卫生技术评估的需求与策略研究［J］. 中国卫生质量管理, 2024,31(12): 22-26.［35］陈孟蕾, 刘 艳, 徐雪慧, 等. 基于智能化效益评估的医疗设备精益管理［J］. 中国卫生质量管理, 2024,31(11): 71-73.

相似文献/References:

[1]唐檬,陈英耀,茅艺伟,等.中国卫生技术评估决策转化现状及影响因素的定性研究[J].中国卫生质量管理,2015,22(06):095.
[2]王海银 张晓溪 房良 金春林.我国卫生技术评估流程规范研究[J].中国卫生质量管理,2016,23(06):060.[doi:10.13912/j.cnki.chqm.2016.23.6.21]
[3]魏巍 张涛 鱼敏.便携式早期清创冲洗器的卫生技术评估[J].中国卫生质量管理,2018,25(03):079.[doi:10.13912/j.cnki.chqm.2018.25.3.24]
[4]张曙欣 陈校云 冯力 宋杨杨 胡可慧 黄婉茹 裴治纲.澳大利亚和新西兰新兴卫生技术水平扫描网络的实践与启示[J].中国卫生质量管理,2019,26(02):106.[doi:10.13912/j.cnki.chqm.2019.26.2.31]
[5]孙辉 金春林 程文迪 房良 王海银.西班牙卫生技术评估的发展应用及启示[J].中国卫生质量管理,2019,26(03):106.[doi:10.13912/j.cnki.chqm.2019.26.3.29]
[6]王海银 丛郦萱 彭颖 王美凤 金春林.我国新医疗技术的定价及支付优化策略探讨[J].中国卫生质量管理,2020,27(01):105.[doi:10.13912/j.cnki.chqm.2020.27.1.27]
[7]程文迪 孙辉 房良 王海银.泰国卫生技术评估机制建设现状及启示[J].中国卫生质量管理,2020,27(01):109.[doi:10.13912/j.cnki.chqm.2020.27.1.28]
[8]邱英鹏赵翔肖月赵羽西.高值医用耗材定义与治理内涵研究[J].中国卫生质量管理,2021,28(05):001.[doi:10.13912/j.cnki.chqm.2021.28.5.01 ]
　QIU Yingpeng,ZHAO Xiang,XIAO Yue.The Definition and Governance Connotation of High Value Medical Consumables[J].Chinese Health Quality Management,2021,28(06):001.[doi:10.13912/j.cnki.chqm.2021.28.5.01 ]
[9]赵羽西邱英鹏肖月.英国高值医用耗材准入及招采管理经验分享：以英格兰为例[J].中国卫生质量管理,2021,28(05):008.[doi:10.13912/j.cnki.chqm.2021.28.5.03 ]
　ZHAO Yuxi,QIU Yingpeng,XIAO Yue.Access and Procurement Management of High Value Medical Consumables in the UK: A Case Study of England[J].Chinese Health Quality Management,2021,28(06):008.[doi:10.13912/j.cnki.chqm.2021.28.5.03 ]
[10]邱英鹏赵羽西赵翔肖月.澳大利亚假体类高值医用耗材医保准入管理经验及启示[J].中国卫生质量管理,2021,28(05):012.[doi:10.13912/j.cnki.chqm.2021.28.5.04 ]
　QIU Yingpeng,ZHAO Yuxi,ZHAO Xiang.Experience in Medical Insurance Access Management of Prosthetic High Value Medical Consumables in Australia and Its Implications[J].Chinese Health Quality Management,2021,28(06):012.[doi:10.13912/j.cnki.chqm.2021.28.5.04 ]

更新日期/Last Update: 2025-06-15